Compositions and methods of treating mammalian diseases using myoblasts,
and/or their physical, genetic, chemical derivatives. Myogenic cells that
are normal, or genetically or phenotypically altered are cultured and
transplanted into malfunctioning and/or degenerative tissues or organs to
alleviate conditions that are hereditary, degenerative, debilitating,
undesirable, and/or fatal. Treatment of these conditions is not limited
to the usage of mechanical, electrical or physical properties of these
myogenic cells, but includes the usage of biochemicals secreted/released
by the latter. The present invention discloses the use of normal
myoblasts to deliver the complete normal genome to effect genetic repair,
or to augment the size, or the function of tissues or organs. Certain
conditions may be better served with genetically altered myogenic cells
derived from gene transduction, whereas others may be better served with
cytoclimes converter cells. Endogenous biochemical(s) are used to control
cell fusion of myoblasts among themselves or with other cell types. An
automated cell processor within a cell bank which enables the
manufacture, at a single run, of unprecedented large quantities (greater
than 100 billion) of normal or genotypically or phenotypically altered
myogenic cells is also disclosed.